SCINAI IMMUNOTHERAPEUTICS LT (SCNI)
US09073Q3039 - ADR
We assign a fundamental rating of 1 out of 10 to SCNI. SCNI was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of SCNI have multiple concerns. SCNI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
SCNI had negative earnings in the past year.
SCNI had a negative operating cash flow in the past year.
SCNI had negative earnings in each of the past 5 years.
SCNI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SCNI has a better Return On Assets (20.69%) than 98.76% of its industry peers.
SCNI's Return On Equity of 25.36% is amongst the best of the industry. SCNI outperforms 97.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 25.36% | ||
| ROIC | N/A |
ROA(3y)-32.4%
ROA(5y)-39.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 561.28%, SCNI belongs to the top of the industry, outperforming 99.29% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for SCNI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 561.28% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SCNI has more shares outstanding than it did 1 year ago.
SCNI has more shares outstanding than it did 5 years ago.
SCNI has a worse debt/assets ratio than last year.
2.2 Solvency
SCNI has an Altman-Z score of -15.05. This is a bad value and indicates that SCNI is not financially healthy and even has some risk of bankruptcy.
SCNI's Altman-Z score of -15.05 is on the low side compared to the rest of the industry. SCNI is outperformed by 82.83% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that SCNI is not too dependend on debt financing.
SCNI has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: SCNI outperforms 41.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.05 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SCNI has a Current Ratio of 1.16. This is a normal value and indicates that SCNI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.16, SCNI is doing worse than 85.66% of the companies in the same industry.
SCNI has a Quick Ratio of 1.16. This is a normal value and indicates that SCNI is financially healthy and should not expect problems in meeting its short term obligations.
SCNI has a Quick ratio of 1.16. This is amonst the worse of the industry: SCNI underperforms 84.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.16 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 108.90% over the past year.
EPS 1Y (TTM)108.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SCNI. In the last year negative earnings were reported.
Also next year SCNI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
SCNI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SCINAI IMMUNOTHERAPEUTICS LT
NASDAQ:SCNI (1/14/2025, 8:04:34 PM)
After market: 3.4 -0.04 (-1.2%)3.4414
+0.02 (+0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.51%
Inst Owner Change0%
Ins Owners7.76%
Ins Owner ChangeN/A
Market Cap2.94M
Analysts82.86
Price Target714 (20647.37%)
Short Float %0.17%
Short Ratio0.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.49 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.29 | ||
| P/tB | 0.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)-18.7
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-7.89
FCFYN/A
OCF(TTM)-7.6
OCFYN/A
SpS0.53
BVpS11.73
TBVpS11.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 25.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 561.28% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-32.4%
ROA(5y)-39.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 19.94% | ||
| Cap/Sales | 54.42% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.16 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | -15.05 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)96.83%
Cap/Depr(5y)198.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y98.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.6%
OCF growth 3YN/A
OCF growth 5YN/A